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Conclusions: Our	meta‐analysis	 found	 that	 galectin‐3	 is	 significantly	 higher	 in	 pa‐
tients	with	persistent	AF	than	in	those	with	paroxysmal	AF,	and	can	predict	both	AF	
development and recurrence after treatment.
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1  | INTRODUC TION
Atrial	 fibrillation	 (AF)	 is	 the	most	common	arrhythmia	observed	 in	











activation,	 has	 emerged	 as	 a	 promising	 biomarker	 for	 risk	 stratifi‐
cation.8	 A	 recent	 meta‐analysis	 has	 demonstrated	 that	 galectin‐3	
provides incremental prognostic value that extends beyond that of 
traditional	risk	factors	in	the	context	of	heart	failure.9	However,	the	
evidence	on	AF	has	been	controversial	with	some	studies	reporting	
prognostic	 values	while	 others	 have	 demonstrated	 little	 utility.	 In	
this	study,	therefore,	we	conducted	a	systematic	review	and	meta‐
analysis of published studies to evaluate the prognostic value of 
galectin‐3	in	the	context	of	AF.




analysis	 (PRISMA)	 statement.	We	 searched	 studies	 that	 examined	
association	 between	 serum	 concentration	 of	 galectin‐3	 and	 atrial	
fibrillation	 (AF).	Two	 independent	 reviewers	 (MG	and	AC)	system‐
atically and independently searched the electronic databases of 
PubMed,	EMBASE,	and	the	Cochrane	Database	to	identify	relevant	
studies	 from	 their	 inception	 through	 June	 24,	 2018.	 The	 search	
terms	used	were	as	follows:	 (galectin	3	or	gal	3)	and	(atrial	fibrilla‐
tion	or	AF).	There	were	no	restrictions	with	date	of	publication	or	
language. The search details of different databases were recorded in 
Table	S1.	Excluded	studies	encompassed	duplicate	studies	or	ineligi‐
ble for our study selection criteria. The disagreement was resolved 
by	discussion	with	a	senior	reviewer	(TL).
2.2 | Selection criteria





ysmal	AF	 group	 and	persistent	AF	 group,	 or	 recurrence	AF	 group	
and	without	 recurrence	AF	group;	 and	d)	 the	hazard	 ratios	 (HRs)/
odds	 ratio	 (OR)	 and	 the	 corresponding	 95%	 confidence	 intervals	
(CI)	or	mean	±	standard	deviation	(SD)	were	reported	for	galectin‐3.	






Two	blinded	reviewers	 (MG	and	AC)	 independently	extracted	 the	
relevant data from each eligible study using a standard data extrac‐
tion	 form	 and	 cross‐checked.	 The	 following	 data	were	 extracted:	
first	 author's	 last	 name,	 publication	 year,	 location,	 study	 design,	
number	of	participants,	male	 ratio,	mean	age,	 duration	of	 follow‐
up,	study	population,	and	measurement	methods	of	galectin‐3.	Any	





To limit heterogeneity secondary to differences among study de‐
signs,	the	methodological	quality	of	included	articles	was	evaluated	
by	 two	 blinded	 reviewers	 (MG	 and	 AC)	 applying	 the	 Newcastle‐
Ottawa	Score	 (NOS)	 checklist.	We	graded	 the	quality	as	good	 (≥7	
stars),	fair	(4‐6	stars),	and	poor	(<4	stars).
2.5 | Statistical analysis
























lication bias was evaluated by inspecting the funnel plot for each 
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outcome.	 Statistical	 significance	was	 defined	 as	 a	 2‐tailed	P‐value	











trol group;13 one study population was heart failure;14 four studies 
lacked	 available	 data	 for	 further	 analysis;15‐18 and four reported 
duplicate data from studies that later published as full text.19‐22 
Finally,	28	studies	involving	10	830	patients	were	included	in	our	
meta‐analysis,23‐50 with their baseline characteristics shown in 
Tables 1 and 2.
Fourteen	 studies	 compared	 serum	 concentrations	 of	 galec‐
tin‐3	 between	 the	 sinus	 rhythm	 group	 and	 AF	 group.26,28,29,31‐
33,37,40,42,44,46,47,49,50	 Our	 meta‐analysis	 shows	 that	 the	 AF	 group	
had	higher	concentrations	of	galectin‐3	than	the	sinus	rhythm	(SR)	
group	(mean	difference	[MD]	=	−0.68	ng/mL,	95%	CI:	−0.92,	−0.44,	









in	 predicting	patients	who	will	 have	AF	 recurrence	 after	 different	
treatments	 for	 SR	 restoration.	 Our	 meta‐analysis	 shows	 that	 pa‐
tients	with	 no	 recurrence	 had	 significantly	 lower	 galectin‐3	 levels	
than	 those	with	 disease	 recurrence	 (MD	 =	 −4.23	 ng/mL,	 95%	CI:	
−6.13,	−2.33,	Z	=	4.37,	P	<	.0001)	(Figure	2D).	Furthermore,	higher	
galectin‐3	levels	were	associated	with	higher	risk	of	AF	recurrence	





AF	 is	 the	most	 frequently	 cardiac	 arrhythmia	 observed	 in	 clinical	
practice,	with	an	increasing	prevalence	due	to	an	aging	population	
and the rising burden of comorbid cardiovascular diseases.51	It	is	im‐
portant at the public health level because of its predisposition to 
stroke,	heart	failure,	dementia,	premature	mortality,	and	disability.52 
In	this	condition,	there	is	an	ongoing	cardiomyopathic	process	of	the	
atrial	myocardium,53,54 involving a number of cellular and molecular 
mechanisms revolving around inflammation.55,56 One of the conse‐
quences	is	fibrosis,	characterized	by	increased	turnover	of	the	extra‐
cellular	matrix,	producing	conduction	abnormalities	that	provide	the	
necessary substrate for arrhythmogenesis.57,58	A	number	of	blood	
biomarkers3,5‐7,59‐62 and electrocardiographic predictors54,63,64 
have	 been	 found	 in	 association	with	 AF	 onset,	 development,	 and	
F I G U R E  1  Flow	diagram	of	study	
selection process
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TA B L E  1  Characteristics	of	included	studies	for	meta‐analysis	of	association	of	galectin‐3	and	AF
















Clementy	2014 France Case‐control Symptomatic	AF 187 NA VIDAS	Galectin‐3	
kit
6
Gurses	2014 Turkey PC Lone	AF	underwent	cryobal‐
loon‐based	PVI
100 12 mo ELISA 6
Ho	2014 United	States PC AF	and	SR 3306 10 y ELISA 7
Lee 2014 China PC AF 96 18 mo ELISA 6
Sonmez	2014 Turkey Case‐control AF	and	SR 85 NA ELISA 7
Yalcin 2014 Turkey Case‐control Lone	AF	and	SR 256 NA ELISA 6
Gurses	2015a Turkey Case‐control AF	and	SR 151 NA ELISA 8
Gurses	2015b Turkey PC Persistent	AF 65 3 mo ELISA 6
Kornej 2015 Germany PC AF	underwent	catheter	
ablation
119 6 mo ELISA 6
Wu 2015 China PC Persistent	AF	and	SR 96 17 mo Milliplex	MAP	Kits 9
A	2016 Russian Case‐control Metabolic	syndrome	with	AF	
and	SR
100 NA ELISA 5
Alexandre	2016 France PC SR	underwent	CABG	with/
without	AVR
137 27 d ELISA 9
Chen	2016 Australia Case‐control New	onset	AF	and	chronic	
AF	(control)
131 NA ELISA 7







230 NA ELISA 5
Mohanty	2016 United	States PC AF	underwent	catheter	
ablation
145 15 mo NA 6
Takemoto	2016 United	States PC AF	underwent	radiofre‐
quency	ablation
55 12 mo ELISA 8
Begg	2017a UK PC Persistent	AF	and	SR 119 383 d ELISA 8
Begg	2017b UK Case‐control Paroxysmal	AF	underwent	
catheter	ablation	and	SR
129 NA ELISA 8
Berger	2017 Netherlands PC AF	underwent	thoracoscopic	
surgical ablation
98 20.7 mo ELISA 6
Dzeshka	2017 Belarus Case‐control Paroxysmal	AF	and	SR 76 NA ELISA 5











Pavlovic 2017 Serbia PC NSTEMI	with	AF	and	SR 54 461 d ELISA 8
Begg	2018 UK PC AF	underwent	radiofre‐
quency	ablation
92 1 y ELISA 7
Kang 2018 China Case‐control AF	underwent	radiofre‐
quency	ablation	and	SR
30 NA ELISA 8
Tang 2018 China PC AF 113 NA ELISA 7
Abbreviations:	AVR,	aortic	valve	replacement;	CABG,	coronary	artery	bypass	graft;	ELISA,	enzyme‐linked	immunosorbent	assay;	PC,	prospective	
cohort;	pPCI,	Primary	percutaneous	coronary	intervention;	PVI,	pulmonary	vein	isolation.
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recurrence.	Of	these,	galectin‐3	plays	a	key	role	in	acute	and	chronic	
pro‐inflammatory	 responses	 and	mediates	 activation	 of	 quiescent	
fibroblasts and synthesis of collagen.65 Previous studies have re‐
ported	the	prognostic	value	of	galectin‐3	in	cardiovascular	patholo‐
gies	 such	 as	 acute	 coronary	 syndrome,66	 heart	 failure,67,68 and in 
the general population.16,69	Recently,	a	meta‐analysis	examined	 its	
prognostic value in the context of heart failure and in the general 
population,9,18	but	whether	 it	 aids	 risk	 stratification	 in	AF	 remains	
controversial.	Several	trends	have	emerged	from	this	meta‐analysis	
regarding	the	correlation	between	galectin‐3	concentrations	and	AF.	
Firstly,	galectin‐3	 levels	are	higher	 in	AF	patients	than	those	 in	SR	






lectin.71	 It	 has	 diverse	 biological	 functions	 such	 as	 regulation	 of	
cell	 adhesion,72	 immunity,73	 inflammation,74 and fibrosis.75	 Its	
pathological	role	 in	the	heart,	specifically	heart	failure,	has	been	
discussed in detail by the excellent review here.76	It	is	upregulated	
in	response	to	increased	stressors	such	as	angiotensin	II	and	pres‐
sure	overload.	It	is	thought	to	play	a	critical	role	in	the	transition	
from	compensatory	 remodeling	 to	decompensation,	 as	originally	
shown in an animal model.77	AF	can	 induce	tissue	 injury,	 leading	
to	 increased	 synthesis	 and	 subsequent	 release	 of	 galectin‐3	 by	
macrophages.77	Galectin‐3	can	itself	mediate	macrophage	activa‐
tion	through	both	classical	and	alternative	pathways,78 as well as 
induce adverse structural and electrophysiological remodeling in 
the atria.42	The	latter	effect	may	be	independent	of	heart	failure,	
since	galectin‐3	 is	 raised	 in	AF	patients	without	 structural	heart	
disease.32	The	following	mechanisms	underlying	galectin‐3‐medi‐
ated atrial dysfunction have been identified. The extracellular pen‐
tameric	domain	of	galectin‐3	can	interact	with	pro‐fibrotic	signals,	
TA B L E  2  Characteristics	of	included	patients	in	the	meta‐analysis
First author Age (years) Male (%) Hypertension (%) Diabetes (%) LAD (mm) LVEF (%)
Szadkowska	2013 61.8	±	10.4 76.3 77.4 24 NR 54.8	±	9.5
Clementy	2014 62	±	10 68 50 18 42	±	7 54	±	11
Gurses	2014 56.95	±	11.36 43.8 0 0 39.1	±	4.7 NR
Ho	2014 58.6	±	9.2 47 NR 14.5 NR NR
Lee 2014 NR NR NR NR NR NR
Sonmez	2014 70	±	10 37 63.2 24.2 NR 53.3	±	12.8
Yalcin 2014 NR NR 0 0 37.1	±	4.4 NR
Gurses	2015a 58.1	±	10.2 47.1 0 0 NR 65.9	±	3.3
Gurses	2015b 56.09	±	8.03 46.2 NR NR NR NR
Kornej 2015 61.5	±	8.6 57.5 NR NR NR NR
Wu 2015 47.6	±	9.4 94.8 0 0 37.6	±	4.7 63.2	±	4.9
A	2016 NR NR NR NR NR NR
Alexandre	2016 67.2	±	10.7 86.7 78.1 38.7 NR 60.5	±	9.9
Chen	2016 70.3	±	11.8 59 52.5 26 NR NR
Clementy	2016 61	±	10 71 49 17 42	±	8 54	±	11
Ionin	2016 50	±	22.4 NR NR NR NR NR
Mohanty	2016 NR 69 NR NR NR NR
Takemoto	2016 62.7	±	1.1 82 NR NR 44.3	±	1.1 59.2	±	0.8
Begg	2017a 62.8	±	10.0 68.8 52.5 13.2 42.8	±	6.1 55.7	±	12.4
Begg	2017b 57.8	±	11.4 69.4 40.2 11.8 40.1	±	6.7 58.5	±	9.2
Berger	2017 59.8	±	8.6 76 57 7 NR 50.2	±	10.3
Dzeshka	2017 62.16 57.5 NR NR NR NR
Fashanu	2017 62.7	±	5.7 41.6 NR 15.5 NR NR
Hernandez‐romero	
2017
65.1	±	9.5 77 70 47 40.71	±	5.80 NR
Pavlovic 2017 68.1	±	10.9 60.6 91.6 29.8 NR 55.12	±	8.9
Begg	2018 58.23	±	15.47 69.9 33.5 10.15 NR NR
Kang 2018 62.45	±	5.14 NR NR NR 38.8	±	3.61 63.25	±	2.49
Tang 2018 66.7	±	9.4 50.6 54.1 22.25 38.6	±	4.9 42.2	±	9.0
Abbreviations:	LAD,	left	atrium	diameter;	LVEF,	left	ventricular	ejection	fraction;	NR,	not	reported.
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such	 as	 transforming	 growth	 factor‐β/SMAD,	 which	 can	 initiate	
fibrosis.39	Furthermore,	galectin‐3	can	form	complexes,	which	can	
cross‐link	glycosylated	ligands	to	form	a	lattice.79 This lattice could 





study	 adhered	 to	PRISMA	guidelines,	which	 ensured	 the	quality	
of	the	systematic	evaluation	and	minimization	of	bias.	Secondly,	a	
large sample size of 10 830 patients from a total of 28 studies was 
included,	meaning	 that	we	 are	 confident.	 Finally,	 galectin‐3	 lev‐
els	were	 determined	 using	 enzyme‐linked	 immunosorbent	 assay	
(ELISA)	 in	21	of	 the	studies,	 and	 therefore.	we	can	be	confident	
that	 the	values	provided	are	comparable.	However,	 some	 limita‐
tions	must	be	noted.	Firstly,	only	14	of	the	28	included	studies	had	
quality	scores	of	7	or	above,	suggesting	quality	of	the	remaining	
14	 studies	 requires	 cautious	 interpretation.	 Secondly,	 attempts	
were made to identify the origin of the high heterogeneity. There 
are	several	reasons	as	to	why	this	may	be	the	case,	for	example,	
differing	characteristics	of	the	study	groups,	such	as	acute	myo‐
cardial	 infarction,	metabolic	 syndrome,	 or	 after	 coronary	 artery	
bypass grafting surgery or ablation procedures; possible variable 
contributions from confounders such as heart failure and other 
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